Lies, damned lies, and statistics!.....the study you highlighted above (but conveniently omitted the link for) includes chemo therapy....whereas CHMs ADVENT AML Phase 1 B expansion cohort "will only enroll older/unfit patients with newly diagnosed adverse or intermediate risk AML or MDS/AML who are ineligible for intensive chemotherapy and/or are ineligible for or decline to receive allo-SCT.
Ann: ADVENT-AML Phase 1B clinical trial update, page-67
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.747M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $1.858K | 619.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 66 | 58647032 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 107164382 | 32 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| CHM (ASX) Chart |